Literature DB >> 24729268

Urological evaluation of patients that had undergone in utero myelomeningocele closure: A prospective assessment at first presentation and early follow-up. Do their bladder benefit from it?

Antonio Macedo1, Marcela Leal1, Atila Rondon1, Valdemar Ortiz1, Antonio Fernandes Moron2,3, Sérgio Cavalheiro4.   

Abstract

AIMS: To report our data on initial urological presentation after in utero myelomeningocele (MMC) closure.
METHODS: A prospective urological assessment at first presentation was designed for patients that had undergone in utero MMC closure and referred to our urological facility. The protocol consisted of detailed medical history, renal sonography, voiding cystourethrogram, and urodynamic evaluation.
RESULTS: In utero MMC closure was performed in 19 patients at gestational age of 25.6 weeks 25-27. Birth occurred at a mean gestational age of 31.8 weeks 26-36. Hyperactive bladder was observed in 89.5% 17/19. Bladder compliance was normal in two cases (10.5%), was markedly reduced in 10 patients (52.6%) and not possible to be determined due to urinary leakage in 7 patients (36.8%). We observed normal bladder capacity in 8 patients (42.1%), reduced in 11 (57.9%), and detrusor-sphincter dyssynergia in 9 patients (47.4%). Underactive bladder was diagnosed in one case. Clean Intermittent Catheterization was initiated by 11 patients (57.9%) mostly in association with anticholinergics 10/11. Vesicoureteral reflux was found in 5 patients (26.3%) and 9 had pyelonephritis at a mean follow-up of 5.4 months 2-17.
CONCLUSIONS: Our data suggested that despite in utero MMC surgery, patients are at risk for bladder abnormal function and renal deterioration and should be aggressively treated, not differently from those operated in the post-natal term. This study has the merit of being a prospectively set evaluation performed by one investigator, including the urodynamic study. We acknowledge the need of long-term follow up.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  fetal surgery; myelomeningocele; spina bifida; urodynamics

Mesh:

Year:  2014        PMID: 24729268     DOI: 10.1002/nau.22576

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  7 in total

Review 1.  Fetal surgery: a critical review.

Authors:  H Kitagawa; K C Pringle
Journal:  Pediatr Surg Int       Date:  2017-01-05       Impact factor: 1.827

Review 2.  Urological Outcomes of Myelomeningocele and Lipomeningocele.

Authors:  Yvonne Y Chan; Samantha K Sandlin; Eric A Kurzrock
Journal:  Curr Urol Rep       Date:  2017-05       Impact factor: 3.092

Review 3.  Fetal surgery for myelomeningocele is effective: a critical look at the whys.

Authors:  Martin Meuli; Ueli Moehrlen
Journal:  Pediatr Surg Int       Date:  2014-06-08       Impact factor: 1.827

4.  Low level myelomeningoceles: do they need prenatal surgery?

Authors:  Pierre-Aurelien Beuriat; Isabelle Poirot; Frederic Hameury; Delphine Demede; Kieron J Sweeney; Alexandru Szathmari; Federico Di Rocco; Carmine Mottolese
Journal:  Childs Nerv Syst       Date:  2019-03-27       Impact factor: 1.475

5.  Bladder Function After Fetal Surgery for Myelomeningocele.

Authors:  John W Brock; Michael C Carr; N Scott Adzick; Pamela K Burrows; John C Thomas; Elizabeth A Thom; Lori J Howell; Jody A Farrell; Mary E Dabrowiak; Diana L Farmer; Earl Y Cheng; Bradley P Kropp; Anthony A Caldamone; Dorothy I Bulas; Susan Tolivaisa; Laurence S Baskin
Journal:  Pediatrics       Date:  2015-10       Impact factor: 7.124

6.  In utero repair of fetal rat myelomeningocele affects neuromuscular development in the bladder.

Authors:  Liangfeng Tang; Haijun Zhong; Hong Chen; Jian Shen; Yunli Bi; Xianmin Xiao
Journal:  Exp Ther Med       Date:  2017-08-21       Impact factor: 2.447

7.  In utero myelomeningocele repair and high-risk bladder pattern. a prospective study.

Authors:  Antonio Macedo; Sérgio Leite Ottoni; Antonio Moron; Sergio Cavalheiro; Marcela Leal da Cruz
Journal:  Int Braz J Urol       Date:  2022 Jul-Aug       Impact factor: 3.050

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.